General anesthetics is one of the major classes of drugs used for general anesthesia. General anesthetics can be administered for a number of medical conditions including but not limited to the following: respiratory problems, such as lung cancer and asthma; cardiac problems, such as congenital heart disease and myocardial infarction; neurological disorders, such as seizures and Parkinson's disease; severe burns and traumatic brain injury. General anesthesia can also be given for cosmetic reasons, such as breast augmentation and nose surgery.
Increasing funding for R&D in anesthetic drugs is expected to propel growth of the general anesthesia drugs market over the forecast period. For instance, in August 2021, researchers at Washington University School of Medicine in St. Louis and the University of Michigan received a US$ 33 million grant from the Patient-Centered Outcomes Research Institute to compare intravenous propofol to inhaled anesthetic drugs to determine which of the common anesthetic drugs offers better patient recovery experiences and improved clinical outcomes.
Product recall is expected to limit growth of the general anesthesia drugs market over the forecast period. For instance, in May 2021, Hospira announced to recall one lot each of the injectable hospital anesthetics bupivacaine HCL and lidocaine HCL due to mislabeling of product.
- This report provides in-depth analysis of the general anesthesia drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global general anesthesia drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, and Hospira Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global general anesthesia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global general anesthesia drugs market
-
- Propofol
- Sevoflurane
- Dexmedetomidine
- Desflurane
- Remifentanil
- Midazolam
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Baxter Healthcare
- Dr. Reddy's Laboratories
- Fresenius KabiPfizer Inc.
- Hikma Pharmaceuticals
- Sagent Pharmaceuticals
- Teva Pharmaceuticals
- Par Pharmaceutical
- Viatris Inc.
- AbbVie
- Piramal Critical Care
- Aspen Global Incorporated
- B. Braun SE
- Abbott
- COSMO PHARMACEUTICALS
- Hospira Inc.
- Maruishi
- Hengrui
- Lunan
